|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:USP32-MAP3K3 (FusionGDB2 ID:96705) |
Fusion Gene Summary for USP32-MAP3K3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: USP32-MAP3K3 | Fusion gene ID: 96705 | Hgene | Tgene | Gene symbol | USP32 | MAP3K3 | Gene ID | 84669 | 4215 |
| Gene name | ubiquitin specific peptidase 32 | mitogen-activated protein kinase kinase kinase 3 | |
| Synonyms | NY-REN-60|USP10 | MAPKKK3|MEKK3 | |
| Cytomap | 17q23.1-q23.2 | 17q23.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ubiquitin carboxyl-terminal hydrolase 32deubiquitinating enzyme 32renal carcinoma antigen NY-REN-60ubiquitin specific protease 32ubiquitin thioesterase 32ubiquitin thiolesterase 32ubiquitin-specific-processing protease 32 | mitogen-activated protein kinase kinase kinase 3MAP/ERK kinase kinase 3MAPK/ERK kinase kinase 3MEK kinase 3MEKK 3 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | Q99759 | |
| Ensembl transtripts involved in fusion gene | ENST00000300896, ENST00000592339, ENST00000393003, ENST00000586881, | ENST00000579585, ENST00000584573, ENST00000361733, ENST00000361357, ENST00000577395, ENST00000577784, | |
| Fusion gene scores | * DoF score | 36 X 25 X 11=9900 | 8 X 11 X 4=352 |
| # samples | 42 | 11 | |
| ** MAII score | log2(42/9900*10)=-4.55896729218821 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(11/352*10)=-1.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: USP32 [Title/Abstract] AND MAP3K3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | USP32(58422842)-MAP3K3(61770909), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | USP32-MAP3K3 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. USP32-MAP3K3 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF. USP32-MAP3K3 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | MAP3K3 | GO:0035556 | intracellular signal transduction | 15001576 |
| Tgene | MAP3K3 | GO:0046777 | protein autophosphorylation | 15001576 |
| Fusion gene breakpoints across USP32 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across MAP3K3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-BH-A0DZ-01A | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
Top |
Fusion Gene ORF analysis for USP32-MAP3K3 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000300896 | ENST00000579585 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| In-frame | ENST00000300896 | ENST00000584573 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| Frame-shift | ENST00000300896 | ENST00000361733 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| In-frame | ENST00000300896 | ENST00000361357 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| Frame-shift | ENST00000300896 | ENST00000577395 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| 5CDS-intron | ENST00000300896 | ENST00000577784 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000592339 | ENST00000579585 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000592339 | ENST00000584573 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000592339 | ENST00000361733 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000592339 | ENST00000361357 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000592339 | ENST00000577395 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-intron | ENST00000592339 | ENST00000577784 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| Frame-shift | ENST00000393003 | ENST00000579585 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| In-frame | ENST00000393003 | ENST00000584573 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| Frame-shift | ENST00000393003 | ENST00000361733 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| In-frame | ENST00000393003 | ENST00000361357 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| Frame-shift | ENST00000393003 | ENST00000577395 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| 5CDS-intron | ENST00000393003 | ENST00000577784 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000586881 | ENST00000579585 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000586881 | ENST00000584573 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000586881 | ENST00000361733 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000586881 | ENST00000361357 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-3CDS | ENST00000586881 | ENST00000577395 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| intron-intron | ENST00000586881 | ENST00000577784 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000300896 | USP32 | chr17 | 58422842 | - | ENST00000584573 | MAP3K3 | chr17 | 61770909 | + | 793 | 381 | 283 | 609 | 108 |
| ENST00000300896 | USP32 | chr17 | 58422842 | - | ENST00000361357 | MAP3K3 | chr17 | 61770909 | + | 3136 | 381 | 1089 | 562 | 175 |
| ENST00000393003 | USP32 | chr17 | 58422842 | - | ENST00000584573 | MAP3K3 | chr17 | 61770909 | + | 634 | 222 | 124 | 450 | 108 |
| ENST00000393003 | USP32 | chr17 | 58422842 | - | ENST00000361357 | MAP3K3 | chr17 | 61770909 | + | 2977 | 222 | 930 | 403 | 175 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000300896 | ENST00000584573 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + | 0.086202554 | 0.9137974 |
| ENST00000300896 | ENST00000361357 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + | 0.45499784 | 0.54500216 |
| ENST00000393003 | ENST00000584573 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + | 0.10982342 | 0.89017653 |
| ENST00000393003 | ENST00000361357 | USP32 | chr17 | 58422842 | - | MAP3K3 | chr17 | 61770909 | + | 0.34695745 | 0.65304255 |
Top |
Fusion Genomic Features for USP32-MAP3K3 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| USP32 | chr17 | 58422841 | - | MAP3K3 | chr17 | 61770908 | + | 0.000137847 | 0.9998621 |
| USP32 | chr17 | 58422841 | - | MAP3K3 | chr17 | 61770908 | + | 0.000137847 | 0.9998621 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for USP32-MAP3K3 |
| Go to FGviewer for the breakpoints of chr17:58422842-chr17:61770909 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | MAP3K3 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Component of a protein kinase signal transduction cascade. Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators. {ECO:0000269|PubMed:12912994, ECO:0000269|PubMed:14661019, ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:9006902}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 241_252 | 62.0 | 1605.0 | Calcium binding | 1 |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 277_288 | 62.0 | 1605.0 | Calcium binding | 2 |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 228_263 | 62.0 | 1605.0 | Domain | EF-hand 2 |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 264_299 | 62.0 | 1605.0 | Domain | EF-hand 3 |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 369_585 | 62.0 | 1605.0 | Domain | DUSP |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 734_1567 | 62.0 | 1605.0 | Domain | Note=USP |
| Hgene | USP32 | chr17:58422842 | chr17:61770909 | ENST00000300896 | - | 2 | 34 | 91_126 | 62.0 | 1605.0 | Domain | EF-hand 1 |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000361357 | 15 | 17 | 362_622 | 581.6666666666666 | 658.0 | Domain | Protein kinase | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000361357 | 15 | 17 | 44_123 | 581.6666666666666 | 658.0 | Domain | PB1 | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000361733 | 14 | 16 | 362_622 | 550.6666666666666 | 627.0 | Domain | Protein kinase | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000361733 | 14 | 16 | 44_123 | 550.6666666666666 | 627.0 | Domain | PB1 | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000579585 | 16 | 18 | 362_622 | 581.6666666666666 | 658.0 | Domain | Protein kinase | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000579585 | 16 | 18 | 44_123 | 581.6666666666666 | 658.0 | Domain | PB1 | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000361357 | 15 | 17 | 368_376 | 581.6666666666666 | 658.0 | Nucleotide binding | ATP | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000361733 | 14 | 16 | 368_376 | 550.6666666666666 | 627.0 | Nucleotide binding | ATP | |
| Tgene | MAP3K3 | chr17:58422842 | chr17:61770909 | ENST00000579585 | 16 | 18 | 368_376 | 581.6666666666666 | 658.0 | Nucleotide binding | ATP |
Top |
Fusion Gene Sequence for USP32-MAP3K3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000300896_ENST00000584573_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(transcript)=793nt_BP=381nt ACGTGATCCGGCATGGAGGCGGTGGCGGCGACCGGGAGGAGCCGCCGGGGCAGAAGCCGCACTTGTTAGTGTGGGGGGAGGTGGGGGCGG GGGACGCCGACACCGTCACCGTCACCCAGGGACGCCGAGGAGAAGGCGGGAGGGGGGTGGGGGCGAGATCAGGCTCCGACCCCCCGCCGA GGGGATGAGGGGAGCATGGGTGCCAAGGAGTCACGGATCGGATTCCTCAGCTACGAGGAGGCGCTGAGGAGAGTTACAGATGTAGAGCTA AAACGACTGAAGGATGCTTTCAAGAGGACCTGTGGACTCTCATATTACATGGGCCAGCACTGCTTCATCCGGGAAGTGCTTGGGGATGGA GTGCCTCCAAAGGTTGCTGAGGAGCCTGGGCTGCACTGTGGTGGAGATGCTGACAGAGAAACCACCGTGGGCAGAGTATGAAGCTATGGC CGCCATCTTCAAGATTGCCACCCAGCCCACCAATCCTCAGCTGCCCTCCCACATCTCTGAACATGGCCGGGACTTCCTGAGGCGCATTTT TGTGGAGGCTCGCCAGAGACCTTCAGCTGAGGAGCTGCTCACACACCACTTTGCACAGCTCATGTACTGAGCTCTCACGGCCACACAGCT GCCGGTCGCCCTTTGCTGCATGGCAGGGGGCTGCTGCTGGGCTCAGTGAAGTTGCTGCTTCTCCCAGGCAAGGCTGTGGACCATGGAGTG >In-frame_ENST00000300896_ENST00000584573_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(amino acids)=108AA_start in transcript=283_stop in transcript=609 MLSRGPVDSHITWASTASSGKCLGMECLQRLLRSLGCTVVEMLTEKPPWAEYEAMAAIFKIATQPTNPQLPSHISEHGRDFLRRIFVEAR -------------------------------------------------------------- >In-frame_ENST00000300896_ENST00000361357_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(transcript)=3136nt_BP=381nt ACGTGATCCGGCATGGAGGCGGTGGCGGCGACCGGGAGGAGCCGCCGGGGCAGAAGCCGCACTTGTTAGTGTGGGGGGAGGTGGGGGCGG GGGACGCCGACACCGTCACCGTCACCCAGGGACGCCGAGGAGAAGGCGGGAGGGGGGTGGGGGCGAGATCAGGCTCCGACCCCCCGCCGA GGGGATGAGGGGAGCATGGGTGCCAAGGAGTCACGGATCGGATTCCTCAGCTACGAGGAGGCGCTGAGGAGAGTTACAGATGTAGAGCTA AAACGACTGAAGGATGCTTTCAAGAGGACCTGTGGACTCTCATATTACATGGGCCAGCACTGCTTCATCCGGGAAGTGCTTGGGGATGGA GTGCCTCCAAAGGTTGCTGAGGAGCCTGGGCTGCACTGTGGTGGAGATGCTGACAGAGAAACCACCGTGGGCAGAGTATGAAGCTATGGC CGCCATCTTCAAGATTGCCACCCAGCCCACCAATCCTCAGCTGCCCTCCCACATCTCTGAACATGGCCGGGACTTCCTGAGGCGCATTTT TGTGGAGGCTCGCCAGAGACCTTCAGCTGAGGAGCTGCTCACACACCACTTTGCACAGCTCATGTACTGAGCTCTCACGGCCACACAGCT GCCGGTCGCCCTTTGCTGCATGGCAGGGGGCTGCTGCTGGGCTCAGTGAAGTTGCTGCTTCTCCCAGGCAAGGCTGTGGACCATGGAGTG GCAGCCCAGCCAGCGTCGGTCTGTGCCCCTTCCGCCACTGGGGCTCAGAGCCGGGGTGGGGTGGCTGCAGCCTCAGGACTGGGAGCCCCC AGCCTGTCAGATCCAGGAGCTCCAGTGTCCTGAGCTCAGCGTGGAGGGGTAGGGGCTGGGAACAGTGTGCAAGGCAGCCGTGGGCCCCAC CCTCGGGGATGTGTCCTGACACTGCAATTGGCACCGAAGCCCAGAGGGTCTGGGGGCACAAGACTGACGCCAGGGTATGAAGAGTGTTAT TTTCATTCAAAGTGTTATTTTGTTTTTCCTTCCAATGTCTGGAGACCACCAGGGCATCTCTGGGCTGGATGAGCTCCCACAAGCCTGAGG GAAAGGCCAGCACTCGCTAGCAGTGGCAGGCAGAGGCCCAGGCTGCCGTCCCCTAGAGTCCCAGGTTGGCTCTGCCAGTCCTGTCCTTTA CCAAAGATGAATGAAGCAAATGTCATGCTGCCTTATTCAGGGAAGGAGGAGCCTGTCCTGCCTGTGGCCATGACCCTGCCTCTCCCAGGC AGGGGCCCGCGATGTGGAACTGCTGCCACTGAGGGGGGATCCAGTTTTGTCAATGCAGTTGTCTCTGTTTTACAAGTTGGAGTCACTCTT ATGCTGTACCCAGTTTCTAAACTGGAGACTGTGTGTGCCCTCTGGGCTCTGAGTACCCCTGCTTTGGGCTTGGGCCTAGGCTGCATTGAA AAGAGCTGAAGGTTGTGGCCTTTGCGCTCCTGGCCCAGCCTTTGTTCCCCACTGGAGCAGAAGGGGAGATGGACGACACGGTCGGGGCAT CTGGCCTGGCCAGTGCCCTGATCCCAGAGAGCCCGAGGAGGTGTCTCAGGCTGCCTGAGTCGTGACCTGCTAGGCCAGAGCCCACTCCAT CTGGTAGAAGGGAAAGCCCATATGCTACCACCAGCTGTGTCCAAAACCGCCAGCTCTGTTCTTCCTCAGCCAGCCTCGCCCATCCCCTTG AGGTCTCAGCCCCTTTCCCTTGTAGCTCCTCCCCTGGAGGGGGAATGGCAGCAGGGGTTGGGGAAACAGCATCTCCAAGCAGCTTAGAGT TGGCCATATTTACCTCAGCCTGGGCGCTGGTCCTTTCTTCCGGCCCCTCCCCTCCAAAATGTGCCTATTGCTAGAGCTCCTCCCTCTCAA CACCCAGTTTCCTTGGGAGTTGTCATTAAAGGAAAAAAAAAAAAAAAAAAGCCAGTGCCCAGGGATGGGCATCTCCAGGGAGCTGGGGAT TAGTGCCAGGCAGCCCTGCCAGCCATGCCTACATCCCCATGGGCACAGAACAAGCCAAAGCCTTCGTTGTATGTTGACGATGCACTTTTA TGAATGTAGTTTCTATCGCTGTTTTTAGCCTTTTCACATCATGTAATGTGAGGCCTTGTACTTGTTAATTTATATCTCAGATCATATTTG ATGGTTTTTATATATATCAATTCTAGACTGTTACAGGTGACGGACGCCTCAAGAGAGAGAAGAGAAAATGAAAGCAGCTGGTTTTGCAGA AGTGTGTGTCGCATGCGCCAGTTGGGCCTGGACCCTCCTGTGTCCATCCCTGTTCCCCCAGGGGCTCTATCAGCCCCTGTACCCCACACT GCCCTCTGAAGACAACACAGGCTCCTGCTTCCACCTCGGCCCTTGCCCAGGGTGGGGCCTGGCCCTCATCTTGACCAAAGCTGCTGTGTG GCAGCTCGGCCTCTCTACGACCCCATCTTGGTGGCTGCACACTCTTCCTGGCCCGCACCCCCATCCCCAGTCCCTGTTCCCCAAGAGGAT ACAGAGCACGGTGCTGGCTGACTCAACTGTGCGTCCCAGGTTCAGGGTCTTACAGAGCTCCACCCCCTGGGGTCTTACCTCACTGGGAAT GTGTTTTGAAAATGAATTTGAAGACAAGCCAACAAACCCTGCACTCCAAAAAAGCAAAACAGACCCTAATTTTTTTGTGCCAAAAACTGT GGACATGCTGGCTCAGCATCCTCAGGACCAAGTTGTTGCTTAATTTATTGTTTTTTAATAACTAATCCAGATAAAAAGTTGTGGGGCTTC AGGGTGACCTGGGCCCAAAGGTTCTGAAGGGCAGTTCCTGGCAGCCCCAGGCTTGCTGTGGGAAGGGGCCGTGCCGTCACTTTCTCATCA TTCCATGGGGTGTGTCTGCCTGGGCCAACTCTGCATGGAGAGGCCAGGGCTGGGGACAGTCCGCACTCTGCCACCCTCCTGCCCCTTCCA CCCACCCCAGCTCTATGTCTGTGTCTGAATTGTGGATCGTGCAGCCATGGTTATTGTGGAACTGTGGAACCTGCAGCCATAGTTATTTGA >In-frame_ENST00000300896_ENST00000361357_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(amino acids)=175AA_start in transcript=1089_stop in transcript=562 MAFPSGLWELIQPRDALVVSRHWKEKQNNTLNENNTLHTLASVLCPQTLWASVPIAVSGHIPEGGAHGCLAHCSQPLPLHAELRTLELLD -------------------------------------------------------------- >In-frame_ENST00000393003_ENST00000584573_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(transcript)=634nt_BP=222nt CAGGCTCCGACCCCCCGCCGAGGGGATGAGGGGAGCATGGGTGCCAAGGAGTCACGGATCGGATTCCTCAGCTACGAGGAGGCGCTGAGG AGAGTTACAGATGTAGAGCTAAAACGACTGAAGGATGCTTTCAAGAGGACCTGTGGACTCTCATATTACATGGGCCAGCACTGCTTCATC CGGGAAGTGCTTGGGGATGGAGTGCCTCCAAAGGTTGCTGAGGAGCCTGGGCTGCACTGTGGTGGAGATGCTGACAGAGAAACCACCGTG GGCAGAGTATGAAGCTATGGCCGCCATCTTCAAGATTGCCACCCAGCCCACCAATCCTCAGCTGCCCTCCCACATCTCTGAACATGGCCG GGACTTCCTGAGGCGCATTTTTGTGGAGGCTCGCCAGAGACCTTCAGCTGAGGAGCTGCTCACACACCACTTTGCACAGCTCATGTACTG AGCTCTCACGGCCACACAGCTGCCGGTCGCCCTTTGCTGCATGGCAGGGGGCTGCTGCTGGGCTCAGTGAAGTTGCTGCTTCTCCCAGGC AAGGCTGTGGACCATGGAGTGGCAGCCCAGCCAGCGTCGGTCTGTGCCCCTTCCGCCACTGGGGCTCAGAGCCGGGGTGGGGTGGCTGCA >In-frame_ENST00000393003_ENST00000584573_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(amino acids)=108AA_start in transcript=124_stop in transcript=450 MLSRGPVDSHITWASTASSGKCLGMECLQRLLRSLGCTVVEMLTEKPPWAEYEAMAAIFKIATQPTNPQLPSHISEHGRDFLRRIFVEAR -------------------------------------------------------------- >In-frame_ENST00000393003_ENST00000361357_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(transcript)=2977nt_BP=222nt CAGGCTCCGACCCCCCGCCGAGGGGATGAGGGGAGCATGGGTGCCAAGGAGTCACGGATCGGATTCCTCAGCTACGAGGAGGCGCTGAGG AGAGTTACAGATGTAGAGCTAAAACGACTGAAGGATGCTTTCAAGAGGACCTGTGGACTCTCATATTACATGGGCCAGCACTGCTTCATC CGGGAAGTGCTTGGGGATGGAGTGCCTCCAAAGGTTGCTGAGGAGCCTGGGCTGCACTGTGGTGGAGATGCTGACAGAGAAACCACCGTG GGCAGAGTATGAAGCTATGGCCGCCATCTTCAAGATTGCCACCCAGCCCACCAATCCTCAGCTGCCCTCCCACATCTCTGAACATGGCCG GGACTTCCTGAGGCGCATTTTTGTGGAGGCTCGCCAGAGACCTTCAGCTGAGGAGCTGCTCACACACCACTTTGCACAGCTCATGTACTG AGCTCTCACGGCCACACAGCTGCCGGTCGCCCTTTGCTGCATGGCAGGGGGCTGCTGCTGGGCTCAGTGAAGTTGCTGCTTCTCCCAGGC AAGGCTGTGGACCATGGAGTGGCAGCCCAGCCAGCGTCGGTCTGTGCCCCTTCCGCCACTGGGGCTCAGAGCCGGGGTGGGGTGGCTGCA GCCTCAGGACTGGGAGCCCCCAGCCTGTCAGATCCAGGAGCTCCAGTGTCCTGAGCTCAGCGTGGAGGGGTAGGGGCTGGGAACAGTGTG CAAGGCAGCCGTGGGCCCCACCCTCGGGGATGTGTCCTGACACTGCAATTGGCACCGAAGCCCAGAGGGTCTGGGGGCACAAGACTGACG CCAGGGTATGAAGAGTGTTATTTTCATTCAAAGTGTTATTTTGTTTTTCCTTCCAATGTCTGGAGACCACCAGGGCATCTCTGGGCTGGA TGAGCTCCCACAAGCCTGAGGGAAAGGCCAGCACTCGCTAGCAGTGGCAGGCAGAGGCCCAGGCTGCCGTCCCCTAGAGTCCCAGGTTGG CTCTGCCAGTCCTGTCCTTTACCAAAGATGAATGAAGCAAATGTCATGCTGCCTTATTCAGGGAAGGAGGAGCCTGTCCTGCCTGTGGCC ATGACCCTGCCTCTCCCAGGCAGGGGCCCGCGATGTGGAACTGCTGCCACTGAGGGGGGATCCAGTTTTGTCAATGCAGTTGTCTCTGTT TTACAAGTTGGAGTCACTCTTATGCTGTACCCAGTTTCTAAACTGGAGACTGTGTGTGCCCTCTGGGCTCTGAGTACCCCTGCTTTGGGC TTGGGCCTAGGCTGCATTGAAAAGAGCTGAAGGTTGTGGCCTTTGCGCTCCTGGCCCAGCCTTTGTTCCCCACTGGAGCAGAAGGGGAGA TGGACGACACGGTCGGGGCATCTGGCCTGGCCAGTGCCCTGATCCCAGAGAGCCCGAGGAGGTGTCTCAGGCTGCCTGAGTCGTGACCTG CTAGGCCAGAGCCCACTCCATCTGGTAGAAGGGAAAGCCCATATGCTACCACCAGCTGTGTCCAAAACCGCCAGCTCTGTTCTTCCTCAG CCAGCCTCGCCCATCCCCTTGAGGTCTCAGCCCCTTTCCCTTGTAGCTCCTCCCCTGGAGGGGGAATGGCAGCAGGGGTTGGGGAAACAG CATCTCCAAGCAGCTTAGAGTTGGCCATATTTACCTCAGCCTGGGCGCTGGTCCTTTCTTCCGGCCCCTCCCCTCCAAAATGTGCCTATT GCTAGAGCTCCTCCCTCTCAACACCCAGTTTCCTTGGGAGTTGTCATTAAAGGAAAAAAAAAAAAAAAAAAGCCAGTGCCCAGGGATGGG CATCTCCAGGGAGCTGGGGATTAGTGCCAGGCAGCCCTGCCAGCCATGCCTACATCCCCATGGGCACAGAACAAGCCAAAGCCTTCGTTG TATGTTGACGATGCACTTTTATGAATGTAGTTTCTATCGCTGTTTTTAGCCTTTTCACATCATGTAATGTGAGGCCTTGTACTTGTTAAT TTATATCTCAGATCATATTTGATGGTTTTTATATATATCAATTCTAGACTGTTACAGGTGACGGACGCCTCAAGAGAGAGAAGAGAAAAT GAAAGCAGCTGGTTTTGCAGAAGTGTGTGTCGCATGCGCCAGTTGGGCCTGGACCCTCCTGTGTCCATCCCTGTTCCCCCAGGGGCTCTA TCAGCCCCTGTACCCCACACTGCCCTCTGAAGACAACACAGGCTCCTGCTTCCACCTCGGCCCTTGCCCAGGGTGGGGCCTGGCCCTCAT CTTGACCAAAGCTGCTGTGTGGCAGCTCGGCCTCTCTACGACCCCATCTTGGTGGCTGCACACTCTTCCTGGCCCGCACCCCCATCCCCA GTCCCTGTTCCCCAAGAGGATACAGAGCACGGTGCTGGCTGACTCAACTGTGCGTCCCAGGTTCAGGGTCTTACAGAGCTCCACCCCCTG GGGTCTTACCTCACTGGGAATGTGTTTTGAAAATGAATTTGAAGACAAGCCAACAAACCCTGCACTCCAAAAAAGCAAAACAGACCCTAA TTTTTTTGTGCCAAAAACTGTGGACATGCTGGCTCAGCATCCTCAGGACCAAGTTGTTGCTTAATTTATTGTTTTTTAATAACTAATCCA GATAAAAAGTTGTGGGGCTTCAGGGTGACCTGGGCCCAAAGGTTCTGAAGGGCAGTTCCTGGCAGCCCCAGGCTTGCTGTGGGAAGGGGC CGTGCCGTCACTTTCTCATCATTCCATGGGGTGTGTCTGCCTGGGCCAACTCTGCATGGAGAGGCCAGGGCTGGGGACAGTCCGCACTCT GCCACCCTCCTGCCCCTTCCACCCACCCCAGCTCTATGTCTGTGTCTGAATTGTGGATCGTGCAGCCATGGTTATTGTGGAACTGTGGAA CCTGCAGCCATAGTTATTTGACTATATCTTGACCGAGGGCTTGCAGTGCAAAGCCAGGCCAGTGTTGCGCATTACTTACAATAAAAGGGA >In-frame_ENST00000393003_ENST00000361357_TCGA-BH-A0DZ-01A_USP32_chr17_58422842_-_MAP3K3_chr17_61770909_length(amino acids)=175AA_start in transcript=930_stop in transcript=403 MAFPSGLWELIQPRDALVVSRHWKEKQNNTLNENNTLHTLASVLCPQTLWASVPIAVSGHIPEGGAHGCLAHCSQPLPLHAELRTLELLD -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for USP32-MAP3K3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for USP32-MAP3K3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | MAP3K3 | Q99759 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | MAP3K3 | Q99759 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | MAP3K3 | Q99759 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for USP32-MAP3K3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | USP32 | C4721610 | Carcinoma, Ovarian Epithelial | 1 | CTD_human |
| Tgene | MAP3K3 | C0014859 | Esophageal Neoplasms | 1 | CTD_human |
| Tgene | MAP3K3 | C0546837 | Malignant neoplasm of esophagus | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies